1. Crawford, J, Dale, DC, Lyman, GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228–237.
2. Tamura, K, Fukuoka, M. Molecular target-based cancer therapy: tyrosine kinase inhibitors. International Journal of Clinical Oncology 2003; 8: 207–211.
3. Sharma, A, Lokeshwar, N. Febrile neutropenia in hematological malignancies. Journal of Postgraduate Medicine 2005; 51 (Suppl. 1): S42–48.
4. Maschmeyer, G, et al. Management of infections during intensive treatment of hematologic malignancies. Annals of Hematology 1997; 75: 9–16.
5. Kuderer, NM, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258–2266.
6. Hughes, WT, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clinical Infectious Dieases 1997; 25: 551–573.
7. Tamura, K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. International Journal of Antimicrobial Agents 2005; 26 (Suppl. 2): S123–127.
8. Link, H, et al. Antimicrobial therapy of unexplained fever in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Annals of Hematology 2003; 82 (Suppl. 2): S105–117.
9. Rolston, KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clinical Infectious Dieases 2005; 40 (Suppl. 4): S246–252.
10. Chen, CY, et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. Journal of Formosa Medical Association 2004; 103: 526–532.
11. Ramphal, R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clinical Infectious Dieases 2004; 39 (Suppl. 1): S25–31.
12. Wisplinghoff, H, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clinical Infectious Diseases 2003; 36: 1103–1110.
13. Viscoli, C. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). European Journal of Cancer 2002; 38 (Suppl. 4): S82–87.
14. Wang, FD, Lin, ML, Liu, CY. Bacteremia in patients with hematological malignancies. Chemotherapy 2005; 51: 147–153.
15. Safdar, A, Rolston, KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clinical Infectious Dieases 2007; 45: 1602–1609.
16. Irfan, S, et al. Emergence of carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infectious Diseases 2008; 8: 80.
17. Ansari, SR, et al. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007; 109: 2615–2622.
18. Cattaneo, C, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with hematological malignancies: results of a prospective study on 823 patients at a single institution. Journal of Antimicrobial Chemotherapy 2008; 61: 721–728.
19. Mutnick, AH, Kirby, JT, Jones, RN. CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance. Annals of Pharmacotherapy 2003; 37: 47–56.
20.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard M2-A9, 9th edn. CLSI, Wayne, PA, 2006.
21.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. M100-S18. CLSI, Wayne, PA, 2008.
22. Hughes, WT, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clinical Infectious Dieases 1997; 25: 551–573.
23.The Infectious Diseases Society of Taiwan, et al. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. Journal of Microbiology, Immunology and Infection 2005; 38: 455–457.
24. Viscoli, C, Castagnola, E. Treatment of febrile neutropenia: what is new? Current Opinion in Infectious Diseases 2002; 15: 377–382.
25. Zinner, SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clinical Infectious Dieases 1999; 29: 490–494.
26. Gaytán-Martínez, J, et al. Microbiological findings in febrile neutropenia. Archives of Medical Research 2000; 31: 388–392.
27. Wisplinghoff, H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Dieases 2004; 39: 309–317.
28. Klastersky, J, et al. Bacteraemia in febrile neutropenic cancer patients. International Journal of Antimicrobial Agents 2007; 30 (Suppl. 1): S51–59.
29. Velasco, E, et al. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. European Journal of Clinical Microbiology and Infectious Diseases 2006; 25: 1–7.
30. Aisenberg, G, et al. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. European Journal of Clinical Microbiology and Infectious Diseases 2007; 26: 13–20.
31. Cometta, A, et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. New England Journal of Medicine 1994; 330: 1240–1241.
32. Munoz-Price, LS, Weinstein, RA. Acinetobacter infection. New England Journal of Medicine 2008; 358: 1271–1281.
33. García-Garmendia, JL, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clinical Infectious Diseases 2001; 33: 939–946.
34. Perez, F, et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2007; 51: 3471–3484.